HIGHLIGHTS
- who: Yvan Arsenijevic and colleagues from the Unit Retinal Degeneration and Regeneration, Department of Ophthalmology, University of Lausanne have published the research work: Lentiviral Vectors for Ocular Gene Therapy, in the Journal: Pharmaceutics 2022, 1605 of 25/07/2022
- what: One of the six serious adverse events (AE) observed during the study was related to the procedure, but none of the serious AE or non-ocular AE were described as potentially linked to the LV itself. This study demonstrated the safety of the LV and the localized expression within the targeted tissue. This work shows . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.